Biomass
$1
+0%
Broad Spectrum Distillate
$3,674
+0%
CBD Isolate
$1,157
-16%
CBG Isolate
$7,408
-1.8%
Hemp Seed Oil
$109
+0%
MCT Oil
$109
+0%
Water Soluble CBD
$2,373
-0.7%
Back to news
29. June 2020
Corporate News News Pharmaceutical

Khiron Partners with Leading German Medical Cannabis Distributor Nimbus Health

Khiron Life Sciences Corp.  (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), has partnered with Nimbus Health, a leading German distributor of medical cannabis products, to distribute Khiron branded EU GMP medical cannabis in Germany for prescription by doctors and dispensation in pharmacies.

Tejinder Virk, President of Khiron Europe, commented: “This is a major milestone for our company. Following our recent entry into the United Kingdom, the expansion into Germany will greatly benefit patients who still suffer from inconsistent supply.  Khiron is now well positioned to service this rapidly expanding market in Germany.

The supply of EU GMP medical cannabis to Germany, in partnership with Nimbus Health, will be fully supported by the Company’s global medical education team, led by Dr. Maria Fernanda Arboleda, Khiron’s International Director for Medical Services. Dr. Arboleda is an Anesthesiologist, Pain and Palliative Care Physician. She completed a Spine-Regional Anesthesia Fellowship at the McGill University Health Center and a Post-Doctoral Research Fellow in Supportive Cancer Care and Medical Cannabis, at the Department of Oncology, McGill University, and at Santé Cannabis, a leading specialized cannabis clinic in Canada.

Franziska Katterbach, Managing Director & Chief Legal Officer for Khiron Europe based in Frankfurt, commented: “Germany continues to be the European leader in medical cannabis, with other countries observing and adapting to the German regulatory model. The market is also differentiated with its large proportion of patient prescriptions fully reimbursed through insurance.”

The move follows the company’s announcement, last month, that it had received the first medical cannabis prescriptions for patients participating in Project Twenty21 in the United Kingdom (UK). Khiron branded EU GMP medical cannabis is now available for prescription from doctors and clinics participating in Project Twenty21, Europe’s largest study of the effectiveness and tolerability of medical cannabis.

Khiron Life Sciences Corp. is the dominant integrated medical cannabis company in Latin America. The Company is fully authorised to manufacture and fill prescriptions for high- and low-THC medical cannabis in Colombia and has the first approved line of CBD cosmetic products on shelf in Colombia, and available in the United States and the United Kingdom.

Source | Khiron Life Sciences Corp.